Nanjing Sanhome Pharmaceutical Co. Ltd
Sanhome was founded in 1996; now it has become a key high-tech pharmaceutical enterprise in China, concentrating on drug development, production and marketing.
Sanhome mainly focuses on drugs for cancer, infection and central nervous system diseases. We have approximately 20 projects at this stage. 3 of them are in clinical trials, and 4 molecules are in pre-clinical stages. More than a dozen effective molecules have been identified.
The mission of Sanhome is Let more people enjoy the joy of health and the enterprise vision is To become the most trustworthy enterprise for doctors and patients by helping patients prolong their life span and improve their quality of life.
Ms Kefan YaoBD manager
Napp Pharmaceuticals Limited
Napp is part of a privately owned global network of independent associated companies. In Europe, Mundipharma and Napp have sales revenues of over $1bn combined.
We are an asset led, highly entrepreneurial and commercially minded business that is focussed on providing innovative medicines to UK patients across all parts of the NHS. We are ambitious to be a leading partnership selling organisation; creating strong and effective partnerships with commercial partners, healthcare providers and patients.
Structured in Business Units around our four commercial platforms of Primary Care, Specialty Care, Biosimilars and Branded Generics, we are able to make fast decisions and focus on the right products in the right areas.
Qdem, our branded generics house is a wholly owned subsidiary of Napp. Qdem has a team of 8 dedicated KAMs who cover the whole of the UK. We have had great success in gaining and maintaining market share with our branded generics Butec®, Longtec® and Shortec®.
Our other leading brands at Napp include Invokana® for Type II diabetes, Flutiform® for asthma and Remsima®, Truxima® and Herzuma® (biosimilars of infliximab, rituximab and trastuzumab).
Napp has exceptionally capable marketing, sales and market access matrix teams, which effectively build and grow originator products in competitive indication areas, and enjoy an excellent reputation in the NHS and with GPs and UK KOLs. Mundipharma has both a heritage and reputation for excellence in pharmaceutical marketing and sales around the world, and an excellent reputation with healthcare practitioners throughout our region.
We have the support and remit to grow quickly our Qdem UK generics business through the in-licensing and acquisition of assets. Our Qdem marketing and sales team consists of originator salespeople from within and outside of the Napp Pharmaceuticals business with superb payer, formulary and healthcare practitioner contacts, and has excellent experience for the launch of both complex and value added branded generics in the UK.
We are interested in:
We are looking for dossiers and supply across all therapy areas (but particularly respiratory, urology, CNS & gastroenterology) for the following:
Value add generics, with novel dose forms or strengths
Generic drug delivery devices
Other complex delivery forms
Delayed or complex release forms across all therapy areas
Napp is keen to explore partnership opportunities for NCEs, biologics, biosimilars, orphan medicines and generics.
We are not interested in
Immediate release generics.
Hospital tender only generics.
API. CRO, CSO or CMO services.
Ms Esi Scott-ArthurBusiness Development & Licensing Manager
Nathura SPA is an Italian manufacturer of food supplements, medical devices and functional cosmetics
The Company is UNI EN ISO 9001:2008 certified and all products are manufactured with natural active ingredients.
Nathura is looking for business partners in the EU/European non EU/ MENA countries to whom prosposing both distribution and/or out-licencing agreements
Bowel wellbeing : intestinal regularity, constipation, abdominal blowing
Sleep disorders: nocturnal awakenings, jet leg, stress, menopause
Metabolic disorders: Non-alcoholic Fatty Liver Disease (NAFLD),metabolic syndrome, insuline-resistance
Vaginal disorders: regenerative complex to protect, moisture and soothe the vulvar mucosa (vulvo-vaginal atrophy)
Dermatologic treatment of superficial wounds/burns/ fissures
Mr Giorgio AmadoriExport Consultant
NATRAPHARM, Philippines www.natrapharm.comCore objective: To market pharmaceutical products through licensing and/or supply agreement with reputable international companies.
Organization: The total headcount is 600, among which 518 are field personnel and 82 in head office (top executives, marketing, registration, finance and HR).
NATRAPHARM Inc. is mainly focussing on antiinfectives, antibiotics, anti-asthma, anti-allergy, pediatricians. The management, the distribution and the services are common to both companies, Natrapharm Inc. and Patriot Pharmaceutical corporation. PATRIOT PHARMACEUTICAL CORPORATION handles cardiology and metabolic, neurology, psychiatry, surgery, pain management, and nephrology.
Sales performance: Natrapharm Group has one of the highest growth rate of the ethical market.
Natrapharm Group is ranking between the 10 leading pharmaceutical companies with more than 70 million US$ (combined drugstore and hospital sales less OTC) and is 2nd largest Filipino pharmaceutical company in the Ethical Segment.
Natrapharm expertise & strengths:
Long experience of partnership with multinational companies
An efficient registration department.
A strong, well trained and motivated promotional force
Licensors: International companies having licensed products to Natrapharm e.g.
Sanofi-Aventis (Phils.), Abbott (Phils.), Ferrer Laboratorios (Spain), Apotex (Canada), MSD (Phils.), Stada (Germany), Samjin (Korea), Ildong (Korea)
The organisation has been built in such a way, that NATRAPHARM has the capacity to market quickly additional products and /lines from new principals.
They have to fit inside NATRAPHARM/PATRIOT current lines and not to compete internally.
They are not necessarily new products but must be marketed in their country of origin and have an up to date registration dossier.
They can also be products already marketed in the Philippines but which is either very little or no longer promoted by the principal due to other priorities.
NATRAPHARM can either take care of a new line if the products can reach a certain level of growth or NATRAPHARM can host the line. In such case, the responsibility remains with the principal.
In any case , NATRAPHARM is looking for a long term relationship between the principal and NATRAPHARM. NATRAPHARM as 2nd largest Pilipino ethical company is open for co-marketing of innovative products from multinationals.
We are interested in:
Ethical, unique, add-on generic products (also niche products) as well as medical food with indication and clinical trials, metoprolol, clonidine, diltiazem, rosuvastatin, nicardipine inj. with CDT format dossier, climate zone IV stability.
Dr. Thomas Högn
International Advisor and Member of the Executive Committee
Natrapharm, Inc., Philippines
Tel.: +49 (0) 172 2910525e-mail: firstname.lastname@example.org
Dr Thomas HögnInternational Advisor Natrapharm
Nicholas Hall Consultancy
Senior Consultant at Nicholas Hall Consultancy. I am the Head the M&A and Licensing department as well as manage strategic consultancy projects (e.g. market entry, product launches, pricing, etc). I, along with my team have helped global pharma companies and private equity firms find suitable acquisition and licensing opportunities. Let's meet to discuss how Nicholas Hall Consultancy can help you.